Italian P&R Group acquires Biofarmitalia and strengthens its leadership in pharmaceutical innovation

The acquired company is a leader in the field of delivery systems and medical devices

Effective October 7th, the P&R SpA Group has completed the acquisition of the Italian based Biofarmitalia.

With its 20-year know-how, Biofarmitalia is a leader in the research and manufacture of transcutaneous patches, impregnated matrices and medical devices for the delivery of active principles by dermal and oral route.

With this acquisition, P&R Group consolidates its leadership in the field of pharmaceuticals and innovative delivery systems, in terms of market share and at R&D level.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine